Please try another search
Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.
Name | Age | Since | Title |
---|---|---|---|
Seigo Kashii | 70 | 2017 | Independent External Director |
Tadahisa S. Kagimoto | 47 | 2012 | Chairman & CEO |
Richard P. Kincaid | 47 | 2018 | CFO, Executive Officer & Internal Director |
Hideki Takeda | 66 | 2017 | Auditor |
Yuko Yogo | 67 | 2022 | Independent Outside Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review